{"id":33764,"date":"2025-05-21T01:07:04","date_gmt":"2025-05-20T17:07:04","guid":{"rendered":"https:\/\/flcube.com\/?p=33764"},"modified":"2025-05-21T01:07:04","modified_gmt":"2025-05-20T17:07:04","slug":"porton-and-hualong-biological-partner-to-advance-matc-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33764","title":{"rendered":"Porton and Hualong Biological Partner to Advance MATC Therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd.\u00a0 has entered into a strategic partnership with Hualong Biological, a leading cancer therapy innovator headquartered in Henan. Porton Advanced will provide comprehensive end-to-end CDMO services for Hualong&#8217;s Multi-Activated T Cell (MATC) therapy, ranging from process optimization to regulatory submission. This collaboration aims to accelerate the development progress of the MATC therapy. Financial details of the partnership were not disclosed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hualong Biological&#8217;s MATC Platform<\/strong><br>Hualong Biological&#8217;s research team has established a robust clinical foundation for its MATC platform through multiple investigator-initiated trials (IITs). These trials have demonstrated significant therapeutic benefits across various solid tumor indications. The MATC therapy has shown promise in addressing unmet needs in cancer treatment, particularly in solid tumors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Porton Advanced&#8217;s Role<\/strong><br>Porton Advanced will leverage its industry-leading process development platforms, GMP manufacturing capabilities, and proven regulatory expertise to optimize the MATC therapy&#8217;s CMC strategy. This collaboration is expected to facilitate the transition of Hualong&#8217;s MATC therapy from the research phase to clinical development, ensuring a streamlined and efficient path to market. By combining Hualong&#8217;s innovative research with Porton Advanced&#8217;s CDMO capabilities, the partnership aims to accelerate the development and commercialization of this promising cancer therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd.\u00a0 has entered into a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33767,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[77,19,4068,455],"class_list":["post-33764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cell-therapy","tag-cro-cmo-cdmo","tag-hualong-biological","tag-porton-pharma-solutions"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Porton and Hualong Biological Partner to Advance MATC Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd.\u00a0 has entered into a strategic partnership with Hualong Biological, a leading cancer therapy innovator headquartered in Henan. Porton Advanced will provide comprehensive end-to-end CDMO services for Hualong&#039;s Multi-Activated T Cell (MATC) therapy, ranging from process optimization to regulatory submission. This collaboration aims to accelerate the development progress of the MATC therapy. Financial details of the partnership were not disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33764\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Porton and Hualong Biological Partner to Advance MATC Therapy\" \/>\n<meta property=\"og:description\" content=\"Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd.\u00a0 has entered into a strategic partnership with Hualong Biological, a leading cancer therapy innovator headquartered in Henan. Porton Advanced will provide comprehensive end-to-end CDMO services for Hualong&#039;s Multi-Activated T Cell (MATC) therapy, ranging from process optimization to regulatory submission. This collaboration aims to accelerate the development progress of the MATC therapy. Financial details of the partnership were not disclosed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33764\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T17:07:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2003-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Porton and Hualong Biological Partner to Advance MATC Therapy\",\"datePublished\":\"2025-05-20T17:07:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764\"},\"wordCount\":220,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2003-1.webp\",\"keywords\":[\"Cell-therapy\",\"CRO \\\/ CMO \\\/ CDMO\",\"Hualong Biological\",\"Porton Pharma Solutions\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33764#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33764\",\"name\":\"Porton and Hualong Biological Partner to Advance MATC Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2003-1.webp\",\"datePublished\":\"2025-05-20T17:07:04+00:00\",\"description\":\"Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd.\u00a0 has entered into a strategic partnership with Hualong Biological, a leading cancer therapy innovator headquartered in Henan. Porton Advanced will provide comprehensive end-to-end CDMO services for Hualong's Multi-Activated T Cell (MATC) therapy, ranging from process optimization to regulatory submission. This collaboration aims to accelerate the development progress of the MATC therapy. Financial details of the partnership were not disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33764\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2003-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2003-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Porton and Hualong Biological Partner to Advance MATC Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33764#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Porton and Hualong Biological Partner to Advance MATC Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Porton and Hualong Biological Partner to Advance MATC Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd.\u00a0 has entered into a strategic partnership with Hualong Biological, a leading cancer therapy innovator headquartered in Henan. Porton Advanced will provide comprehensive end-to-end CDMO services for Hualong's Multi-Activated T Cell (MATC) therapy, ranging from process optimization to regulatory submission. This collaboration aims to accelerate the development progress of the MATC therapy. Financial details of the partnership were not disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33764","og_locale":"en_US","og_type":"article","og_title":"Porton and Hualong Biological Partner to Advance MATC Therapy","og_description":"Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd.\u00a0 has entered into a strategic partnership with Hualong Biological, a leading cancer therapy innovator headquartered in Henan. Porton Advanced will provide comprehensive end-to-end CDMO services for Hualong's Multi-Activated T Cell (MATC) therapy, ranging from process optimization to regulatory submission. This collaboration aims to accelerate the development progress of the MATC therapy. Financial details of the partnership were not disclosed.","og_url":"https:\/\/flcube.com\/?p=33764","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-20T17:07:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2003-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33764#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33764"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Porton and Hualong Biological Partner to Advance MATC Therapy","datePublished":"2025-05-20T17:07:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33764"},"wordCount":220,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33764#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2003-1.webp","keywords":["Cell-therapy","CRO \/ CMO \/ CDMO","Hualong Biological","Porton Pharma Solutions"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33764#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33764","url":"https:\/\/flcube.com\/?p=33764","name":"Porton and Hualong Biological Partner to Advance MATC Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33764#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33764#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2003-1.webp","datePublished":"2025-05-20T17:07:04+00:00","description":"Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd.\u00a0 has entered into a strategic partnership with Hualong Biological, a leading cancer therapy innovator headquartered in Henan. Porton Advanced will provide comprehensive end-to-end CDMO services for Hualong's Multi-Activated T Cell (MATC) therapy, ranging from process optimization to regulatory submission. This collaboration aims to accelerate the development progress of the MATC therapy. Financial details of the partnership were not disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33764#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33764"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33764#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2003-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2003-1.webp","width":1080,"height":608,"caption":"Porton and Hualong Biological Partner to Advance MATC Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33764#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Porton and Hualong Biological Partner to Advance MATC Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2003-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33764"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33764\/revisions"}],"predecessor-version":[{"id":33768,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33764\/revisions\/33768"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33767"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}